Compare YDES & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YDES | DSU |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 607.9M |
| IPO Year | N/A | 1998 |
| Metric | YDES | DSU |
|---|---|---|
| Price | $4.44 | $9.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.9K | ★ 304.1K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $9.31 |
| 52 Week High | $25.00 | $10.66 |
| Indicator | YDES | DSU |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 44.00 |
| Support Level | N/A | $9.75 |
| Resistance Level | $5.37 | $9.95 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.03 | 11.90 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.